| Project/Area Number |
24591582
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Pediatrics
|
|---|
| Research Institution | Fukushima Medical University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
HOSOSYA Mitsuaki 福島県立医科大学, 医学部, 教授 (80192318)
KAWASAKI Yukihiko 福島県立医科大学, 医学部, 准教授 (00305369)
HASHIMOTO Yuko 福島県立医科大学, 医学部, 教授 (60305357)
SUZUTANI Tatsuo 福島県立医科大学, 医学部, 教授 (40196895)
|
|---|
| Project Period (FY) |
2012-04-01 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2014: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2013: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2012: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Keywords | RSV / ワクチン / マウスモデル / マウス |
|---|
| Outline of Final Research Achievements |
Respiratory syncytial virus, RSV, is one of the leading cause of respiratory failure in infants and young children, particularly high risk children with a history of premature birth or congenital heart disease. However, there is no effective vaccine for RSV and pharmacologic treatment is far from optimal. Palivizumab is an RSV-neutralizing humanized monoclonal antibody that reacts with a highly conserved region on the RSV fusion protein to inhibit viral replication. Monthly administration of palivizumab to preterm infants has been shown to reduce the incidence of hospitalization due to RSV lower respiratory tract infection. However, the adaptation of the passive immunity with the monoclonal antibody is restrictive. Development of RSV vaccine is desired earnestly. In this study, we investigate effect of vaccine for RSV using with RSV murine model which was established in our only facilities in Japan, virologically, immunologically, physiologically, and histopathologically.
|
